Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT04792593 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

B-ALL

Interventions

BIOLOGICAL: Senl-h19 CAR-T

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.